AU2022340987A1 - Dosing regimen for a tead inhibitor - Google Patents

Dosing regimen for a tead inhibitor Download PDF

Info

Publication number
AU2022340987A1
AU2022340987A1 AU2022340987A AU2022340987A AU2022340987A1 AU 2022340987 A1 AU2022340987 A1 AU 2022340987A1 AU 2022340987 A AU2022340987 A AU 2022340987A AU 2022340987 A AU2022340987 A AU 2022340987A AU 2022340987 A1 AU2022340987 A1 AU 2022340987A1
Authority
AU
Australia
Prior art keywords
cancer
tead
treatment
pharmaceutically acceptable
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2022340987A
Other languages
English (en)
Inventor
Emilie Chapeau
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Publication of AU2022340987A1 publication Critical patent/AU2022340987A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2022340987A 2021-09-01 2022-08-30 Dosing regimen for a tead inhibitor Pending AU2022340987A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163239506P 2021-09-01 2021-09-01
US63/239,506 2021-09-01
PCT/IB2022/058130 WO2023031798A1 (en) 2021-09-01 2022-08-30 Dosing regimen for a tead inhibitor

Publications (1)

Publication Number Publication Date
AU2022340987A1 true AU2022340987A1 (en) 2024-01-18

Family

ID=83355146

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2022340987A Pending AU2022340987A1 (en) 2021-09-01 2022-08-30 Dosing regimen for a tead inhibitor

Country Status (11)

Country Link
US (1) US20240358720A1 (https=)
EP (1) EP4395768A1 (https=)
JP (1) JP2024532325A (https=)
KR (1) KR20240055021A (https=)
CN (1) CN117835977A (https=)
AU (1) AU2022340987A1 (https=)
CA (1) CA3225444A1 (https=)
IL (1) IL309246A (https=)
MX (1) MX2024002566A (https=)
TW (1) TW202327579A (https=)
WO (1) WO2023031798A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119968359A (zh) 2022-09-29 2025-05-09 英矽智能科技知识产权有限公司 Tead抑制剂及其使用方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3156404A1 (en) * 2015-10-15 2017-04-19 Inventiva New compounds inhibitors of the yap/taz-tead interaction and their use in the treatment of malignant mesothelioma
CA3142351A1 (en) 2019-05-31 2020-12-03 Ikena Oncology, Inc. Tead inhibitors and uses thereof
EP4030233B1 (en) 2019-09-18 2025-05-07 Ningbo Sunny Opotech Co., Ltd. Periscopic camera module and electronic device
UY39129A (es) 2020-03-16 2021-10-29 Novartis Ag Derivados de biarilo como inhibidores de la interacción proteína-proteína de yap/taz-tead
CA3205726A1 (en) 2021-01-25 2022-07-28 Alfredo C. Castro Combination of a 3-(imidazol-4-yl)-4-(amino)-benzenesulfonamide tead inhibitor with an egfr inhibitor and/or mek inhibitor for use in the treatment of lung cancer

Also Published As

Publication number Publication date
IL309246A (en) 2024-02-01
US20240358720A1 (en) 2024-10-31
MX2024002566A (es) 2024-03-20
EP4395768A1 (en) 2024-07-10
JP2024532325A (ja) 2024-09-05
WO2023031798A1 (en) 2023-03-09
KR20240055021A (ko) 2024-04-26
CN117835977A (zh) 2024-04-05
CA3225444A1 (en) 2023-03-09
TW202327579A (zh) 2023-07-16

Similar Documents

Publication Publication Date Title
JP6141958B2 (ja) 増殖性疾患の治療のための併用療法（ベムラフェニブ及びｍｄｍ２阻害剤）
JP2020172521A (ja) 薬学的組成物及び方法
KR102634247B1 (ko) 다발성 골수종을 치료하기 위한 약물 병용물
JP6911048B2 (ja) がんの処置において使用するための、Ｎｏｔｃｈ阻害剤およびＰＩ３Ｋ／ｍＴＯＲ阻害剤を用いた併用療法
CN107427522A (zh) 用于治疗黑素瘤的阿吡莫德
WO2023035223A1 (zh) 药物组合物及其用途
WO2012080151A1 (en) Combination therapy comprising vemurafenib and an interferon for use in the treatment of cancer
JP2025163103A (ja) 放射線および／または抗がん治療補助療法としてアデノシン二リン酸リボースの活用
US20240358720A1 (en) Dosing Regimen for a TEAD inhibitor
US20230038138A1 (en) Combination therapy for treating cancer
CN111617081B (zh) 一种取代丁烯酰胺联合mTOR抑制剂的药物组合物及其用途
WO2023281413A1 (en) Methods and dosing regimens comprising pf-06873600 for the treatment of cancer
TW202500147A (zh) 雌激素受體降解劑與ｃｄｋ７抑制劑之組合
WO2025229127A1 (en) A halogenated-heteroaryl kinase inhibitor for treating soft tissue sarcoma and vascular tumors
CN121889151A (zh) Wee1抑制剂和pkmyt1抑制剂的组合
AU2021432315A1 (en) Treating cancer in patient having co-occurring genetic alteration in fgfr2 and a cancer driver gene
EP4093398A1 (en) Abt-751 and ionizing radiation
HK1185808B (en) Combination therapy comprising vemurafenib and an interferon for use in the treatment of cancer